Literature DB >> 3080047

Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

K P Harris, G I Russell, S D Parvin, P S Veitch, J Walls.   

Abstract

Thirteen non-diabetic renal transplant recipients had various aspects of carbohydrate and lipid metabolism studied before and after conversion from cyclosporin A to azathioprine. No patient had a glucose tolerance test result diagnostic of diabetes mellitus before conversion, and there was no change in fasting glucose or immunoreactive insulin values after conversion. There was, however, a fall in the area under the curve of the glucose tolerance test values after conversion. Furthermore, fasting serum cholesterol and triglyceride concentrations fell significantly after conversion. No change in the concentration of high density lipoprotein cholesterol was detected. These findings suggest that cyclosporin A is associated with an inferior lipid profile as compared with azathioprine, which may be important in patients with transplants given the drug long term.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080047      PMCID: PMC1338971          DOI: 10.1136/bmj.292.6512.16

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Effects of cyclosporin on prednisolone metabolism.

Authors:  L Ost
Journal:  Lancet       Date:  1984-02-25       Impact factor: 79.321

2.  Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporin.

Authors:  R Gunnarsson; G Klintmalm; G Lundgren; H Wilczek; J Ostman; C G Groth
Journal:  Lancet       Date:  1983-09-03       Impact factor: 79.321

3.  Cyclosporin.

Authors:  R Y Calne
Journal:  Nephron       Date:  1980       Impact factor: 2.847

Review 4.  Lipid abnormalities in uremia, dialysis, and transplantation.

Authors:  M K Chan; Z Varghese; J F Moorhead
Journal:  Kidney Int       Date:  1981-05       Impact factor: 10.612

5.  The effect of renal transplantation with a minimal steroid regime on uraemic hypertriglyceridaemia.

Authors:  C Turgan; G I Russell; F Baker; J Walls
Journal:  Q J Med       Date:  1984
  5 in total
  12 in total

1.  Transplantation and lipids.

Authors:  D Gossard; J Langlais
Journal:  CMAJ       Date:  1991-04-15       Impact factor: 8.262

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.

Authors:  A Gamba; F Mamprin; R Fiocchi; M Senni; G Troise; P Ferrazzi; R Ferrara; G Corbetta
Journal:  Clin Cardiol       Date:  1997-09       Impact factor: 2.882

Review 4.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Vascular effects of cyclosporine A in vivo and in vitro.

Authors:  G Ferns; M Reidy; R Ross
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

Review 7.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

8.  Long-term metabolic control after pancreas transplantation with enteric exocrine diversion.

Authors:  J Bolinder; G Tydén; A Tibell; C G Groth; J Ostman
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

Review 9.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.